BRAINTREE, Mass., Sept. 10 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today that the Company will be hosting investor meetings during September. As part of these meetings, Haemonetics’ management will review previously discussed guidance which is unchanged from the Company’s August 1, 2008 press release.
The content of the meeting presentations is available on the Company’s website at http://www.haemonetics.com/site/content/km/presentations.asp.
Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
CONTACT: Julie Fallon of Haemonetics Corporation, +1-781-356-9517, or
+1-617-320-2401
Web site: http://www.haemonetics.com/
http://www.haemonetics.com/site/content/km/presentations.asp/
